1. Posterior Reversible Encephalopathy Syndrome: Risk Factors and Impact on the Outcome in Children With Acute Lymphoblastic Leukemia Treated With Nordic Protocols.
- Author
-
Banerjee JS, Heyman M, Palomäki M, Lähteenmäki P, Arola M, Riikonen PV, Möttönen MI, Lönnqvist T, Taskinen MH, and Harila-Saari AH
- Subjects
- Adolescent, Child, Child, Preschool, Epilepsy etiology, Female, Finland epidemiology, Humans, Hypertension etiology, Incidence, Induction Chemotherapy adverse effects, Infant, Male, Posterior Leukoencephalopathy Syndrome epidemiology, Posterior Leukoencephalopathy Syndrome etiology, Precursor Cell Lymphoblastic Leukemia-Lymphoma drug therapy, Precursor Cell Lymphoblastic Leukemia-Lymphoma mortality, Prognosis, Retrospective Studies, Risk Factors, Seizures etiology, Survival Analysis, Posterior Leukoencephalopathy Syndrome chemically induced, Precursor Cell Lymphoblastic Leukemia-Lymphoma complications
- Abstract
Posterior reversible encephalopathy syndrome (PRES) in children with acute lymphoblastic leukemia has been increasingly recognized as a clinicoradiological entity. Our aim was to describe the incidence of PRES in pediatric patients with ALL, identify its risk factors, and examine its prognostic importance. For this research, we conducted a systematic, retrospective review of the patient records in a population-based series of children with acute lymphoblastic leukemia (n=643) treated in Finland from 1992 to 2008. Of the patients with ALL, 4.5% (n=29) developed radiologically confirmed PRES, of which 28 cases occurred during induction. Hypertension (P=0.006; odds ratio [OR], 4.10, confidence interval [CI], 1.50-11.25), constipation (P=0.001; OR, 5.60; CI, 2.02-15.52), and >14 days of alkalinization (P=0.017; OR, 3.27; CI, 1.23-8.68) were significant independent risk factors for PRES. One-third of the patients developed epilepsy. Relapses occurred significantly more often in those patients with PRES (P=0.001), which was associated with worse overall survival (P=0.040; 5-year survival=75.9% [60.3%-91.4%] vs. 88.4% [85.8%-90.9%]). Using NOPHO-ALL 92/2000 protocols, PRES is a significant early complication of therapy in ALL, and was associated with a poorer prognosis and significant neurological morbidity.
- Published
- 2018
- Full Text
- View/download PDF